--- title: FidoCure blog | Vet description: Vet | Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates. --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) # FidoCure Veterinary Team Blog ### Read the latest in veterinary oncology research and FidoCure scientific and clinical updates from our team of experts and advisors Select Category Case Studies Press Vet Webinars This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. Posts about: ## Vet ![FidoCure Genetic Testing Matter](https://blog.fidocure.com/hubfs/Fidocure_LinkedIn_Blog_25July2025.jpg) ### [Why Genetic Testing Matters Before Using Targeted Small Molecule Therapies in Cancer Treatment](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment) *Lucas Rodrigues, DVM, MS, PhD Head of Veterinary Research at FidoCure* Precision medicine has revolutionized human oncology by enabling treatments tailored to the unique genetic makeup of each tumor. Now, this same approach is being increasingly adopted in veterinary medicine, bringing a new level of sophistication to cancer care in dogs. Small molecule targeted therapies are at the forefront of this movement, offering the potential for more effective and individualized treatments. However, **their success depends on a critical first step: identifying the genetic drivers behind each tumor**. Without this information, the use of targeted therapies becomes a gamble, especially risky in aggressive cancers with diverse genetic profiles, where delays in effective treatment can have serious consequences. [Read More](https://blog.fidocure.com/fidocure-blog/why-genetic-testing-matters-before-using-targeted-small-molecule-therapies-in-cancer-treatment) ![](https://blog.fidocure.com/hubfs/Template%20Blog%20Sized%20%20(2).png) ### [Global Impact from the U.S. to Korea at FAVA 2024](https://blog.fidocure.com/fidocure-blog/fava) We are excited to share that Dr. Lucas Rodrigues, FidoCure's Head of Veterinary Research, will be presenting twice at the [23rd Federation of Asian Veterinary Associations (FAVA) Congress](https://www.fava2024.org/sub01/welcome.html), taking place from October 25 to October 27, 2024. This event marks an important opportunity for us to engage with veterinary professionals from around the world and contribute to the ongoing dialogue about canine cancer treatment. [Read More](https://blog.fidocure.com/fidocure-blog/fava) ![](https://blog.fidocure.com/hubfs/3.jpg) ### [Celebrating 5 Years of Research at  AACR](https://blog.fidocure.com/fidocure-blog/aacr5years) **FidoCure by the One Health Company and Stanford University Research Shared at AACR 2024 ** [Read More](https://blog.fidocure.com/fidocure-blog/aacr5years) ![](https://blog.fidocure.com/hubfs/iStock-1258105499.jpg) ### [Innovative Bioinformatics Pipeline Reduces Costs and Expands Access to Precision Therapeutics for Canine Oncology](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology) Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript ["Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics,](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4)" recently published in[Scientific Reports](https://www.nature.com/articles/s41598-023-37505-2?fbclid=IwAR0dZ8PUQB3BmX-8OeySAKt-1aMPmHqPeJId93WhmpeweMEKGq0XkBwRLw4). [Read More](https://blog.fidocure.com/fidocure-blog/innovative-bioinformatics-pipeline-reduces-costs-and-expands-access-to-precision-therapeutics-for-canine-oncology) ![](https://blog.fidocure.com/hubfs/Identification%20of%20genomic%20alterations%20with%20clinical%20impact%20in%20canine%20splenic%20hemangiosarcoma%20(6).png) ### [Canine Cancer Osteosarcoma Research](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition. [Read More](https://blog.fidocure.com/fidocure-blog/canine-cancer-osteosarcoma-research) ![](https://blog.fidocure.com/hubfs/iStock-1128072732.jpg) ### [Veterinary Technician Week: Giveaway](https://blog.fidocure.com/fidocure-blog/vettechgiveaway) ##### **Thank you to all the veterinary technicians who have helped us enroll over 4500 dogs on the FidoCure platform. We are so thankful for your partnership in fighting cancer on both ends of the leash! ** Enter below for your chance to win: [Read More](https://blog.fidocure.com/fidocure-blog/vettechgiveaway) ![](https://blog.fidocure.com/hubfs/Cancer%20does%20not%20have%20to%20be%20a%20death%20sentence.%20(4).png) ### [Cancer Does Not Have to Be a Death Sentence](https://blog.fidocure.com/fidocure-blog/cancer-does-not-have-to-be-a-death-sentence)   [Read More](https://blog.fidocure.com/fidocure-blog/cancer-does-not-have-to-be-a-death-sentence) ### [The DNA from dog tumors may hold the secret to better human cancer drug](https://blog.fidocure.com/fidocure-blog/the-dna-from-dog-tumors-may-hold-the-secret-to-better-human-cancer-drug) ![stat-plus-logo.svg](https://blog.fidocure.com/hs-fs/hubfs/stat-plus-logo.svg.png?width=150&height=33&name=stat-plus-logo.svg.png) [Read More](https://blog.fidocure.com/fidocure-blog/the-dna-from-dog-tumors-may-hold-the-secret-to-better-human-cancer-drug) ![](https://blog.fidocure.com/hubfs/iStock-164853650%20(1).jpg) ### [5 Ways FidoCure Can Expand Your Veterinary Practice](https://blog.fidocure.com/fidocure-blog/5ways) Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure provides targeted therapies that are transforming the landscape of canine cancer care. [Read More](https://blog.fidocure.com/fidocure-blog/5ways) ![](https://blog.fidocure.com/hubfs/ardent.png) ### [Ardent and FidoCure Announce Groundbreaking Partnership](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer) FOR IMMEDIATE RELEASE [Read More](https://blog.fidocure.com/fidocure-blog/ardent-and-fidocure-announce-groundbreaking-partnership-to-increase-access-to-precision-medicine-treatments-for-pet-cancer) [1](https://blog.fidocure.com/fidocure-blog/tag/vet) [2](https://blog.fidocure.com/fidocure-blog/tag/vet/page/2) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved